Cardiol Therapeutics' CardiolRx Reduces Left Ventricular Mass by 9.2g in 109 Patients
Cardiol Therapeutics published Phase II ARCHER trial data showing CardiolRx in 109 acute myocarditis patients reduced left ventricular mass by 9.2g versus placebo (p=0.0117) with decreased left atrial remodeling and favorable inflammatory marker trends. CardiolRx was well tolerated, boosting confidence in pivotal Phase III MAVERIC trial for recurrent pericarditis.
1. ARCHER Phase II Trial Results
Cardiol Therapeutics reported that its randomized, double-blind, placebo-controlled ARCHER study enrolled 109 acute myocarditis patients and demonstrated CardiolRx reduced left ventricular mass by 9.2g versus placebo (p=0.0117), with concurrent decreases in left atrial remodeling and positive trends across multiple inflammation markers.
2. Safety and Tolerability
CardiolRx was well tolerated among participants, with no significant adverse events reported, confirming a favorable safety profile essential for further development in inflammatory heart disease.
3. Impact on Phase III MAVERIC Trial
The robust biological signals observed in ARCHER strengthen confidence in the design and potential success of the ongoing pivotal Phase III MAVERIC trial targeting recurrent pericarditis, where similar inflammasome pathway modulation is expected to deliver meaningful patient outcomes.